Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15973457rdf:typepubmed:Citationlld:pubmed
pubmed-article:15973457lifeskim:mentionsumls-concept:C0150369lld:lifeskim
pubmed-article:15973457lifeskim:mentionsumls-concept:C0027022lld:lifeskim
pubmed-article:15973457lifeskim:mentionsumls-concept:C1521991lld:lifeskim
pubmed-article:15973457lifeskim:mentionsumls-concept:C0302350lld:lifeskim
pubmed-article:15973457lifeskim:mentionsumls-concept:C1514983lld:lifeskim
pubmed-article:15973457lifeskim:mentionsumls-concept:C0449435lld:lifeskim
pubmed-article:15973457pubmed:issue8lld:pubmed
pubmed-article:15973457pubmed:dateCreated2005-7-21lld:pubmed
pubmed-article:15973457pubmed:abstractTextThe t(6;9)(p23;q34) is a recurrent chromosomal abnormality observed in 1% of acute myelogenous leukemia (AML), which generates a fusion transcript between DEK and CAN/NUP214 genes. We used a DEK-CAN real-time quantitative (RQ)-PCR strategy to analyze 79 retrospective and prospective samples from 12 patients. Five patients reached DEK-CAN negativity (sensitivity 10(-5)); all underwent early allogeneic hematopoietic stem cell transplantation (median 5.5 months from diagnosis) with some demonstrating molecular positivity at the time of allograft. All four cases in CCR with adequate follow-up (median 18.5 months, range 13--95) demonstrate persistent molecular negativity, whereas all seven patients with persistent DEK-CAN positivity died at a median of 12 months from diagnosis (range 7--27). We conclude that DEK-CAN molecular monitoring by RQ-PCR in t(6;9) malignancies is a useful tool for individual patient management and that molecular negativity is indispensable for survival, but should not be a prerequisite for allografting in this rare, poor prognosis, subset of AML.lld:pubmed
pubmed-article:15973457pubmed:languageenglld:pubmed
pubmed-article:15973457pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15973457pubmed:citationSubsetIMlld:pubmed
pubmed-article:15973457pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15973457pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15973457pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15973457pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15973457pubmed:statusMEDLINElld:pubmed
pubmed-article:15973457pubmed:monthAuglld:pubmed
pubmed-article:15973457pubmed:issn0887-6924lld:pubmed
pubmed-article:15973457pubmed:authorpubmed-author:BergerCClld:pubmed
pubmed-article:15973457pubmed:authorpubmed-author:SchmittCClld:pubmed
pubmed-article:15973457pubmed:authorpubmed-author:ValensiFFlld:pubmed
pubmed-article:15973457pubmed:authorpubmed-author:GarçonLLlld:pubmed
pubmed-article:15973457pubmed:authorpubmed-author:MacintyreEElld:pubmed
pubmed-article:15973457pubmed:authorpubmed-author:LiburaMMlld:pubmed
pubmed-article:15973457pubmed:authorpubmed-author:LeblancTTlld:pubmed
pubmed-article:15973457pubmed:authorpubmed-author:DelabesseEElld:pubmed
pubmed-article:15973457pubmed:authorpubmed-author:BuzynAAlld:pubmed
pubmed-article:15973457pubmed:authorpubmed-author:AsnafiVVlld:pubmed
pubmed-article:15973457pubmed:copyrightInfoLeukemia (2005) 1344.19, 1338- doilld:pubmed
pubmed-article:15973457pubmed:issnTypePrintlld:pubmed
pubmed-article:15973457pubmed:volume19lld:pubmed
pubmed-article:15973457pubmed:ownerNLMlld:pubmed
pubmed-article:15973457pubmed:authorsCompleteYlld:pubmed
pubmed-article:15973457pubmed:pagination1338-44lld:pubmed
pubmed-article:15973457pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15973457pubmed:meshHeadingpubmed-meshheading:15973457...lld:pubmed
pubmed-article:15973457pubmed:meshHeadingpubmed-meshheading:15973457...lld:pubmed
pubmed-article:15973457pubmed:meshHeadingpubmed-meshheading:15973457...lld:pubmed
pubmed-article:15973457pubmed:meshHeadingpubmed-meshheading:15973457...lld:pubmed
pubmed-article:15973457pubmed:meshHeadingpubmed-meshheading:15973457...lld:pubmed
pubmed-article:15973457pubmed:meshHeadingpubmed-meshheading:15973457...lld:pubmed
pubmed-article:15973457pubmed:meshHeadingpubmed-meshheading:15973457...lld:pubmed
pubmed-article:15973457pubmed:meshHeadingpubmed-meshheading:15973457...lld:pubmed
pubmed-article:15973457pubmed:meshHeadingpubmed-meshheading:15973457...lld:pubmed
pubmed-article:15973457pubmed:meshHeadingpubmed-meshheading:15973457...lld:pubmed
pubmed-article:15973457pubmed:meshHeadingpubmed-meshheading:15973457...lld:pubmed
pubmed-article:15973457pubmed:meshHeadingpubmed-meshheading:15973457...lld:pubmed
pubmed-article:15973457pubmed:meshHeadingpubmed-meshheading:15973457...lld:pubmed
pubmed-article:15973457pubmed:meshHeadingpubmed-meshheading:15973457...lld:pubmed
pubmed-article:15973457pubmed:meshHeadingpubmed-meshheading:15973457...lld:pubmed
pubmed-article:15973457pubmed:meshHeadingpubmed-meshheading:15973457...lld:pubmed
pubmed-article:15973457pubmed:meshHeadingpubmed-meshheading:15973457...lld:pubmed
pubmed-article:15973457pubmed:meshHeadingpubmed-meshheading:15973457...lld:pubmed
pubmed-article:15973457pubmed:year2005lld:pubmed
pubmed-article:15973457pubmed:articleTitleDEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification.lld:pubmed
pubmed-article:15973457pubmed:affiliationFaculté de Medecine, Université Paris-Descartes, INSERM EMI U210 and AP-HP Hématologie-biologique, Hôpital Necker- Enfants Malades, rue de Sèvres, Paris cedex, France.lld:pubmed
pubmed-article:15973457pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15973457pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15973457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15973457lld:pubmed